FNY Investment Advisers LLC Purchases Shares of 25,000 Pacific Biosciences of California, Inc. (NASDAQ:PACB)

FNY Investment Advisers LLC acquired a new position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 25,000 shares of the biotechnology company’s stock, valued at approximately $45,000.

Other institutional investors also recently made changes to their positions in the company. ARK Investment Management LLC raised its position in Pacific Biosciences of California by 0.6% in the 3rd quarter. ARK Investment Management LLC now owns 33,406,401 shares of the biotechnology company’s stock worth $56,791,000 after purchasing an additional 193,947 shares during the period. Geode Capital Management LLC grew its stake in shares of Pacific Biosciences of California by 3.7% during the third quarter. Geode Capital Management LLC now owns 6,327,906 shares of the biotechnology company’s stock valued at $10,759,000 after buying an additional 225,034 shares during the last quarter. State Street Corp lifted its stake in shares of Pacific Biosciences of California by 5.7% in the 3rd quarter. State Street Corp now owns 6,276,156 shares of the biotechnology company’s stock valued at $10,669,000 after acquiring an additional 340,766 shares during the last quarter. Soros Fund Management LLC lifted its stake in shares of Pacific Biosciences of California by 23.6% in the 3rd quarter. Soros Fund Management LLC now owns 2,098,000 shares of the biotechnology company’s stock valued at $3,567,000 after acquiring an additional 400,000 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Pacific Biosciences of California by 4.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,040,303 shares of the biotechnology company’s stock valued at $3,469,000 after acquiring an additional 82,807 shares during the period.

Insider Transactions at Pacific Biosciences of California

In related news, insider Oene Mark Van sold 34,405 shares of the company’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $2.03, for a total value of $69,842.15. Following the sale, the insider now directly owns 1,597,454 shares of the company’s stock, valued at $3,242,831.62. This represents a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 2.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on PACB shares. Scotiabank decreased their price target on Pacific Biosciences of California from $7.00 to $6.00 and set a “sector outperform” rating on the stock in a research note on Monday, November 11th. StockNews.com raised shares of Pacific Biosciences of California to a “sell” rating in a research note on Thursday, January 9th. UBS Group cut shares of Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $2.00 price target for the company. in a research report on Monday, November 11th. Finally, Piper Sandler raised their price target on shares of Pacific Biosciences of California from $2.00 to $2.50 and gave the stock a “neutral” rating in a report on Monday, November 11th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $2.95.

Pacific Biosciences of California Stock Performance

Shares of PACB opened at $1.75 on Thursday. The company has a debt-to-equity ratio of 1.97, a current ratio of 9.74 and a quick ratio of 8.64. Pacific Biosciences of California, Inc. has a one year low of $1.16 and a one year high of $7.50. The company has a 50-day simple moving average of $1.97 and a two-hundred day simple moving average of $1.80. The firm has a market capitalization of $477.89 million, a PE ratio of -1.20 and a beta of 1.95.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.